Valuation: Insmed Incorporated

Market Cap 22.35B 19.41B 18.03B 16.63B 31.32B 2,134B 31.89B 213B 83.57B 1,060B 83.94B 82.1B 3,564B P/E 2026 *
-40.4x
P/E 2027 * 204x
Enterprise Value 21.79B 18.93B 17.57B 16.21B 30.53B 2,080B 31.08B 208B 81.46B 1,033B 81.82B 80.03B 3,474B EV / Sales 2026 *
12.8x
EV / Sales 2027 * 7.7x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day-1.94%
1 week-6.01%
Current month-5.31%
1 month-5.31%
3 months-25.94%
6 months-35.64%
Current year-41.99%
1 week 99.03
Extreme 99.03
108.27
1 month 99.03
Extreme 99.03
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.94
Extreme 20.94
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
-2.03%-6.01%-4.01%+357.04% 22.35B
-3.74%-6.32%+42.70%+63.37% 55.2B
-0.81%-0.33%+27.15%+81.12% 55.6B
-0.10%+0.84%-15.64%-14.73% 23.51B
-4.01%-2.68%+12.50%-12.70% 20.6B
-1.23%-3.15%+26.00%-33.84% 17.45B
-3.34%-6.96%+22.02%+515.48% 15.16B
+0.84%+0.14%+51.21%+182.75% 13.91B
-5.09%-13.14%+151.85%+272.20% 13.74B
-10.78%-9.81%+69.06%+138.70% 12.61B
Average -2.94%-1.54%+38.28%+154.94% 25.01B
Weighted average by Cap. -2.54%-0.51%+32.48%+122.49%

Financials

2026 *2027 *
Net sales 1.7B 1.48B 1.37B 1.27B 2.38B 162B 2.43B 16.24B 6.36B 80.65B 6.39B 6.25B 271B 2.78B 2.41B 2.24B 2.07B 3.89B 265B 3.96B 26.51B 10.38B 132B 10.43B 10.2B 443B
Net income -561M -488M -453M -418M -787M -53.59B -801M -5.36B -2.1B -26.61B -2.11B -2.06B -89.5B 71.64M 62.22M 57.78M 53.29M 100M 6.84B 102M 684M 268M 3.4B 269M 263M 11.42B
Net Debt -563M -489M -454M -419M -789M -53.76B -803M -5.38B -2.11B -26.7B -2.11B -2.07B -89.78B -979M -850M -789M -728M -1.37B -93.42B -1.4B -9.34B -3.66B -46.4B -3.67B -3.59B -156B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-30 US$100.82 -2.23% 1,963,273
26-07-29 US$103.12 -0.97% 2,195,533
26-07-28 US$104.13 -0.57% 1,945,719
26-07-27 US$104.73 -2.05% 1,899,713
26-07-24 US$106.92 -0.46% 1,908,298
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
103.12USD
Average target price
196.18USD
Spread / Average Target
+90.25%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock